Valeant Pharmaceuticals, the big Canadian-based group that has owned Bausch & Lomb since last year, sent a letter to Allergan's shareholders on Oct. 27 stating that it was prepared to increase the proposed price of its takeover offer again from $72 to $200 per share. The new offer coincided with ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.